Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDOXS Study (Reducing Deaths due to Oxidative Stress)
2007-001831-73Phase 3Completed
- Sponsor
- Kingston General Hospital
- Start
- Oct 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alanyl glutamine and selenium in critical illness (4 arms), sponsored by Kingston General Hospital. Primary endpoint: 28-day mortality. Started Oct 2008; status: completed.
02
Drugs
alanyl glutamineselenium
03
Conditions
critical illness
Beyond the preview
Go deeper on 2007-001831-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001831-73.